BRPI0416266A - método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente - Google Patents
método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um pacienteInfo
- Publication number
- BRPI0416266A BRPI0416266A BRPI0416266-8A BRPI0416266A BRPI0416266A BR PI0416266 A BRPI0416266 A BR PI0416266A BR PI0416266 A BRPI0416266 A BR PI0416266A BR PI0416266 A BRPI0416266 A BR PI0416266A
- Authority
- BR
- Brazil
- Prior art keywords
- asbestos
- disorder
- treating
- preventing
- controlling
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 239000010425 asbestos Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 229910052895 riebeckite Inorganic materials 0.000 title abstract 3
- 229940118135 JNK inhibitor Drugs 0.000 abstract 1
- 239000012825 JNK inhibitor Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51860103P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/037084 WO2005046594A2 (en) | 2003-11-06 | 2004-11-04 | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416266A true BRPI0416266A (pt) | 2007-01-09 |
Family
ID=34590281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416266-8A BRPI0416266A (pt) | 2003-11-06 | 2004-11-04 | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070270448A1 (https=) |
| EP (1) | EP1684690A4 (https=) |
| JP (1) | JP2007510671A (https=) |
| KR (1) | KR20060124610A (https=) |
| CN (1) | CN1901903A (https=) |
| AU (1) | AU2004288715A1 (https=) |
| BR (1) | BRPI0416266A (https=) |
| CA (1) | CA2544591A1 (https=) |
| IL (1) | IL175428A0 (https=) |
| WO (1) | WO2005046594A2 (https=) |
| ZA (1) | ZA200603719B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| JP2011529504A (ja) | 2008-07-28 | 2011-12-08 | ギリアード サイエンシーズ， インコーポレイテッド | シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物 |
| US20100183633A1 (en) * | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| WO2010144378A2 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| WO2018035454A1 (en) * | 2016-08-19 | 2018-02-22 | Memorial Sloan-Kettering Cancer Center | Methods of differentiating stem cells into endoderm |
| CN113698408B (zh) * | 2020-05-22 | 2025-07-25 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3095415A (en) * | 1958-05-30 | 1963-06-25 | Ciba Ltd | Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group |
| CH428043A (fr) * | 1965-08-16 | 1967-01-15 | Sandoz Ag | Procédé de fabrication de colorants de dispersion isothiazolantroniques |
| US3541110A (en) * | 1967-01-20 | 1970-11-17 | American Home Prod | Indazole-5-sulfonamides |
| JPS63184364A (ja) * | 1987-01-27 | 1988-07-29 | Toshiba Corp | 半導体装置の製造方法 |
| DK0851753T3 (da) * | 1995-09-19 | 2004-03-15 | Fujisawa Pharmaceutical Co | Aerosolpræparater |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0973767A1 (en) * | 1997-03-31 | 2000-01-26 | Dupont Pharmaceuticals Company | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| DE69821011T3 (de) * | 1997-10-02 | 2009-01-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| HK1053107A1 (zh) * | 1999-08-19 | 2003-10-10 | Signal Pharmaceuticals, Inc. | 作为jnk抗化剂的pyrazoloanthrone及其衍生物和它们的成份 |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| US6987184B2 (en) * | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| AU2003217961B2 (en) * | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| AU2004293443A1 (en) * | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc. | Indazole Compounds and methods of use thereof as protein kinase inhibitors |
-
2004
- 2004-11-04 AU AU2004288715A patent/AU2004288715A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/037084 patent/WO2005046594A2/en not_active Ceased
- 2004-11-04 JP JP2006538531A patent/JP2007510671A/ja active Pending
- 2004-11-04 EP EP04800843A patent/EP1684690A4/en not_active Withdrawn
- 2004-11-04 CN CNA2004800400028A patent/CN1901903A/zh active Pending
- 2004-11-04 CA CA002544591A patent/CA2544591A1/en not_active Abandoned
- 2004-11-04 US US10/578,809 patent/US20070270448A1/en not_active Abandoned
- 2004-11-04 BR BRPI0416266-8A patent/BRPI0416266A/pt not_active IP Right Cessation
- 2004-11-04 KR KR1020067011021A patent/KR20060124610A/ko not_active Withdrawn
- 2004-11-04 ZA ZA200603719A patent/ZA200603719B/en unknown
-
2006
- 2006-05-04 IL IL175428A patent/IL175428A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005046594A2 (en) | 2005-05-26 |
| AU2004288715A1 (en) | 2005-05-26 |
| CN1901903A (zh) | 2007-01-24 |
| CA2544591A1 (en) | 2005-05-26 |
| WO2005046594A3 (en) | 2005-09-22 |
| US20070270448A1 (en) | 2007-11-22 |
| JP2007510671A (ja) | 2007-04-26 |
| EP1684690A2 (en) | 2006-08-02 |
| EP1684690A4 (en) | 2008-10-15 |
| ZA200603719B (en) | 2007-09-26 |
| IL175428A0 (en) | 2008-04-13 |
| KR20060124610A (ko) | 2006-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| BRPI0415971A (pt) | método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica | |
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| BRPI0518282A2 (pt) | uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio | |
| AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
| BRPI0510110A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
| BR0315593A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| BRPI0510166A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BRPI0519030A2 (pt) | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| BRPI0416266A (pt) | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| BR0315931A (pt) | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica | |
| BR0107721A (pt) | Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas | |
| BRPI0510167A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar | |
| BRPI0413474A (pt) | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais | |
| BRPI0408113A (pt) | métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |